Previous studies demonstrate that chronic, but not acute electroconvulsive seizures (ECS), increases levels of DFosB, a long-lasting transcription factor, in the hippocampus, and this effect correlates with the slow onset and long-lasting clinical effects of antidepressant treatment. To understand how DFosB mediates long-term plasticity in the hippocampus, we analyzed the gene expression profile of inducible transgenic mice expressing DFosB with a highly sensitive microarray assay and a customized computer analysis program. The CCAAT-enhancing binding protein-b (C/EBPb) was identified as one of the genes downregulated by DFosB in the hippocampus. The downregulation of C/EBPb in the inducible DFosB transgenic mice was confirmed by other quantitative assays including real-time RT-PCR and low density dot blotting. Analysis of the C/EBPb expression in the hippocampus of rats treated with ECS revealed that the C/EBPb mRNA was also downregulated by chronic, but not acute ECS administration, the most effective treatment for depression. Given the reported role of C/EBPb in behavioral conditioning models, it is possible that the DFosB-mediated downregulation of C/EBPb in the hippocampus may be a molecular mechanism by which antidepressants alleviate some of the symptoms of depressed patients.
INTRODUCTION
Electroconvulsive seizure (ECS) therapy is one of the most effective antidepressants and the treatment of choice for depressed patients who do not respond to chemical medications (Franco-Bronson, 1996; Stewart and Reid, 2000; Duman, 2002; Nestler et al, 2002) . Although electroconvulsive therapy has been used for many years, the molecular mechanisms underlying the efficacy of this treatment remain largely unknown. Since repeated administration of ECS is required for its full clinical efficacy, gradual neural adaptive changes in response to repeated treatment may underlie the molecular mechanism of its antidepressant action (Duman et al, 1997 (Duman et al, , 2000 Nestler et al, 2002) . Another important feature of ECS treatment is that its antidepressant effect can last for a relatively long period of time after the final treatment, which suggests that the therapeutic changes are relatively stable. Therefore, transcription factors and regulation of neural gene expression may play an important role in the mood-elevating effects of chronic ECS treatment.
One transcription factor implicated in the actions of antidepressant treatment is the cAMP response elementbinding protein (CREB) (Nibuya et al, 1996; Manji and Duman, 2001) . Levels of CREB and of CREB-mediated transcription are increased in the hippocampus and cerebral cortex by chronic antidepressant treatments, including ECS (Nibuya et al, 1996; Thome et al, 2000; Koch et al, 2002; Nakagawa et al, 2002) . This upregulation of CREB may help restore normal cAMP signaling in these brain regions, whereas abnormally low levels of CREB in depressed patients have been reported (Dowlatshahi et al, 1998; D'Sa and Duman, 2002) . Overexpression of CREB in the rat hippocampus by viral gene transfer results in antidepressant-like effects in models of depression (ie the forced swim and learned helplessness tests), which supports a role for CREB in the action of antidepressants . One of the potential target genes regulated by CREB is brain-derived neurotrophic factor (BDNF). Chronic antidepressant treatment increases BDNF expression in the hippocampus (Nibuya et al, 1995 (Nibuya et al, , 1996 , and this induction is absent in mice lacking the CREB gene (Conti et al, 2002) . Antidepressant induction of BDNF could then have palliative effects on several aspects of the hippocampal function and ease certain symptoms of depression.
Another transcription factor that has been implicated in the action of antidepressants is DFosB. The expression of DFosB is gradually induced in the hippocampus and cerebral cortex by chronic administration of antidepressants, most notably by chronic ECS (Hope et al, 1994; Nestler et al, 1999; Nestler, 2001) . DFosB is an alternatively spliced variant of the fosB gene. Like c-Fos, DFosB forms heterodimers with Jun proteins, mainly JunD, to form active activator protein-1 (AP-1) complexes, which then bind to AP-1 sites in the promoter regions of many neural genes (Chen et al, 2000) . DFosB lacks a portion of the C-terminus, which is the major transactivation domain of full-length FosB (Nakabeppu et al, 1993) . Therefore, DFosB may be a weak transcriptional activator and in some cases may function as a transcriptional repressor (Nakabeppu and Nathans, 1991) . Several downstream target genes for DFosB have been identified to date, including NMDAR1, GluR2, cyclin-dependent kinase-5 (Cdk5), and NF-kB (Hiroi et al, 1998; Kelz et al, 1999; Chen et al, 2000; Ang et al, 2001) .
DFosB is unique with respect to its temporal properties of expression. Two major DFosB isoforms, of 35 and 37 kDa proteins, are generated by chronic ECS treatment from a single open reading frame, presumably by post-translational modification (Chen et al, 1997) . These DFosB isoforms are highly stable proteins, which means that they gradually accumulate in neurons over the course of repeated ECS treatment (Hope et al, 1994) . The gradual induction of DFosB, and its persistence after a course of chronic treatment correlate with the slow onset and long-lasting effects of antidepressant treatments, which suggests that DFosB may be an important mediator of antidepressant action. Understanding how DFosB produces its functional effects could, therefore, provide an insight into the molecular mechanisms of antidepressant treatments.
In this study, we searched for downstream target genes for DFosB using DNA microarrays to analyze the gene expression profiles in the hippocampus of inducible transgenic mice that overexpress DFosB. The CCAATenhancing binding protein-b (C/EBPb) was identified as a target gene downregulated by DFosB. The downregulation of C/EBPb was confirmed in the hippocampus of rats treated with chronic ECS treatment. The possible role of C/ EBPb in the actions of ECS and antidepressant treatment is discussed.
MATERIALS AND METHODS

Transgenic Mice
Inducible transgenic mice were developed as described previously (Chen et al, 1998) . Male 10-week-old bitransgenic 11A mice that express DFosB in an inducible and brain region-specific manner (including the hippocampus), were used in these studies . The mice were conceived and raised on doxycycline (100 mg/ml) in the drinking water to suppress DFosB expression completely (Chen et al, 1998) . Half of the littermates were removed from doxycycline at 3-4 weeks of age and were used 6 weeks later, at which time DFosB expression is induced. The hippocampus was removed from decapitated mice by gross dissection. All the transgenic mice used in this study were maintained in strict accordance with the guidelines established by the National Institutes of Health and the Yale institutional animal care committee.
cDNA Microarrays
Total RNA was isolated from the hippocampus of inducible DFosB transgenic mice using RNAqueous phenol-free total RNA isolation kit (Ambion). A total of 3 mg of total RNA was used to generate cDNA probes, which were fluorescently labeled using Cy3 or Cy5 dendrimers (Genisphere Inc.), independent of base composition or transcription length. The three-dimensional DNA dendrimer for amplification of signals was named 3DNA technology. The dual cDNA probes were hybridized to 4.6k mouse cDNA expression arrays produced by the Yale microarray facility. The arrays were hybridized overnight, subjected to posthybridization washes, and then scanned with a GenePix scanner 4000A (Axon Instruments).
Real-Time RT-PCR
A sensitive Sybr Green-based protocol that can reliably detect two-fold differences in gene expression was used (Newton et al, 2001) . Total RNA was isolated from the hippocampus of transgenic mice using the phenol-free total RNA isolation kit, RNAqueous (Ambion, Austin, TX). In all, 40 ng of total RNA was used for cDNA synthesis using oligo dT primers and Sensiscript reverse transcriptase (Qiagen). After first strand cDNA synthesis, RNA was degraded by NaOH treatment, followed by precipitation of the cDNA using pellet paint coprecipitant (Novagen). The pellet was resuspended in 20 ml nuclease-free water and 1 ml aliquots were used in each PCR reaction, assembled using the Quantitect PCR kit (Qiagen) and primers specific for C/EBPb or cyclophilin. PCR products were amplified in the SmartCycler real-time PCR machine (Cepheid) followed by melt curve analysis and gel electrophoresis to verify specificity and purity of product. All the C/EBPb data were normalized to the housekeeping gene, cyclophilin.
C/EBPb cDNA Dot Blot
C/EBPb and C/EBPa were PCR amplified from whole rat brain cDNA using gene-specific primers. The PCR products were then spotted in duplicate on Nylon membrane (Hybond +, Amersham) in 100 mM NaOH buffer using a robotic microarrayer (Omnigrid, GeneMachines). Radiolabeled (P 33 ) cDNA probes were generated from total hippocampal RNA of the hippocampus of mice expressing DFosB or controls housed with doxycycline in the water and not expressing DFosB. Filters were hybridized overnight in Microhyb buffer (ResGen), washed at high stringency, and exposed to phosphorimager screens. Spot intensity was quantified using Optiquant software (Packard Instruments) and data analysis was performed with Microsoft Excel.
ECS daily for 10 days. The control animals received chronic sham treatment, in which electrodes were clipped onto the rats' ears but no current was applied. For chronic treatment, rats were killed 18 h after the last of 10 daily ECS treatments. Prior sham treatments were used to reduce the effects of stress. The hippocampus was obtained by gross dissection.
Western Blotting
Western blotting was performed as described previously (Hope et al, 1994) . Hippocampus was homogenized in EMSA buffer, aliquots (containing 50 mg of protein) were applied to a 10% acrylamide/0.27% N,N-methylenebisacrylamide resolving gel for SDS-PAGE overnight at 75 V, and then electrotransferred to nitrocellulose at 200 mA for 3 h. Blots were blocked with four 15 min changes of 2% nonfat dry milk in PBS-Tween (PBS containing 0.1% Tween 20) and then incubated overnight on a shaker at 41C in a 1 : 4000 dilution of anti-Fos-related antigen (FRA) antibody (kindly provided by Dr Michael Iadarola, National Institute of Dental Research, NIH) in blocking buffer with 0.05% sodium azide. After washing four times for 15 min each in blocking buffer, blots were incubated for 2 h in a 1 : 4000 dilution of goat anti-rabbit antibody conjugated to horseradish peroxidase (Vector Laboratories, Burlingame, CA) in blocking buffer. The blots were washed eight times for 15 min each with PBS-Tween alone, developed with the enhanced chemiluminescence (ECL) system of Amersham (Arlington Heights, IL), and exposed to Hyperfilm-ECL (Amersham) for 5-60 s. For C/EBPb Western blot analysis, homogenates of the hippocampus (in 1% SDS) were subjected to gel electrophoresis as described above and then blots were incubated with a 1 : 400 dilution of the anti-C/EBPb antibody (Santa Cruz). After washing, the blots were incubated in a 1 : 5000 dilution of goat anti-rabbit antibody conjugated to horseradish peroxidase. Relative levels of DFosB and C/EBPb immunoreactive bands were quantified by measuring the optical density of specific bands in the film using an NIH image 1.62 analysis system.
Microsoft Excel-Based Macros for Microarray Data Analysis
Customized software was designed for analysis of microarray data from the DNA microarrays. The software contains several Microsoft excel-based macros. It was used to process single set or multiple sets of data and extract genes that are regulated in the same direction or in the opposite direction. The software was written in Visual Basic.
RESULTS
DNA Expression Profiling
To identify the gene targets regulated by DFosB we utilized the tetracycline-inducible transgenic strategy ( Figure 1a ). In this system tetracycline binds to the tetracycline-transactivator (tTA) and causes a conformational change that blocks the binding of this protein to its promoter and thereby blocks expression of the downstream transgene, in this case DFosB (Chen et al, 1998; Kelz et al, 1999) . The neuronspecific enolase promoter was used to drive expression of tTA and in the absence of tetracycline, this results in transgene expression largely in forebrain regions, including the hippocampus (Figure 2 ) (Chen et al, 1998; Kelz et al, 1999) . In the present study, mice were conceived and raised on doxycycline, a tetracycline analogue with higher affinity and better brain penetrance, until 3-4 weeks of age. At this point, doxycycline was removed from the drinking water of half of the littermates and the hippocampus was isolated 6 weeks later (approximately 10 weeks of age). Messenger RNA was extracted from the hippocampus of DFosBpositive and -negative mice and used for cDNA synthesis and labeling with Cy5 and Cy3 fluorescent dyes, respectively (Figure 1b) . One advantage of microarray assays using Cy5 and Cy3 dye-labeled probes is that two probes can be mixed together and hybridized to a single microarray. (Chen et al, 1998) . Gene 1 encodes the tTA under the control of the neuron-specific enolase (NSE) promoter. Gene 2 encodes DFosB under the control of the tetracycline-responsive promoter with seven tetracycline operators (TetOp). (b) Strategy for identifying downstream target genes regulated by DFosB in the hippocampus of the inducible transgenic mice. Total RNA was isolated from bitransgenic mice, either expressing or not expressing DFosB. Total RNA samples were used as templates for the synthesis of Cy3-and Cy5-labeled cDNA probes using 3DNA technology. The cDNA probes were hybridized to the arrays, which were then analyzed by the Genepix scanner.
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A highly sensitive microarray assay was developed (Newton et al, 2001 ) using 3DNA technology, which applies three-dimensional DNA dendrimers to enhance the signals by 200-fold. Using this assay and probes derived from hippocampal RNA samples from inducible DFosB transgenic mice, we detected 3950 signals at 4two-fold background levels out of 4592 cDNA spots on a mouse cDNA microarray (Figure 3) . To determine the variation of the microarray assay per se, we made Cy3-and Cy5-labeled probes using the same hippocampal RNA sample, mixed the probes, and hybridized them to microarrays. More than 99% of the detected signals show less than two-fold variation (unpublished data), which suggests that the confidence level of the assay is more than 99% if two-fold regulation is used as a cutoff value. Since our microarrays were designed by an in-house facility, we developed Microsoft excel-based software written in Visual Basic for analysis of microarray data from the special arrays. Using the software, raw data transfer, elimination of spots with irregular shape and with high background signal, data normalization, statistical analyses, extracting information related to the regulated genes, and clustering of the regulated genes in functional groups were readily accomplished.
Identification of C/EBPb as a Downstream Target Gene for DFosB
We analyzed hippocampal RNA samples from three pairs of inducible transgenic mice. The expression of the DFosB transgene in one of each pair of mice was induced by removal of doxycycline from the drinking water. The other three littermates were maintained on doxycycline, which completely suppresses expression of the transgene and these mice served as controls. Genes regulated by two-fold or more were clustered in six groups: kinases, receptors, transcription factors, ion channels, phosphatases, and proteases (Table 1) . Using this strategy we found only genes that were downregulated by two-fold or greater by the expression of DFosB. No difference was observed when the Cy3 and Cy5 labeling was switched. There were several genes of interest, particularly several different classes of protein kinases. In addition, we found that C/EBPb was downregulated by 73% in the hippocampus of the inducible transgenic mice expressing DFosB. Since C/EBPb is induced in the hippocampus in behavioral learning paradigms and may be required for consolidation of the memory of fearful stimuli (Taubenfeld et al, 2001) , it was of interest to characterize further the regulation of C/EBPb by DFosB and ECS treatment.
Confirmation of C/EBPb Downregulation in the Inducible Transgenic Mice Expressing DFosB
DNA microarrays represent semiquantitative assays and the results must be confirmed by more quantitative approaches. We isolated RNA samples from the hippocampus of five pairs of inducible DFosB transgenic mice, and analyzed the samples by quantitative real-time RT-PCR (Figure 4) . The results showed that the C/EBPb mRNA is downregulated in the transgenic mice overexpressing DFosB (Figure 4) . To confirm further the regulation of the C/EBPb expression by DFosB, RNA samples were isolated from the hippocampus of new groups of the inducible DFosB transgenic mice, and subjected to cDNA dot blotting with radioactive isotopelabeled probes for C/EBPb. The results of the RNA dot blot also demonstrate that C/EBPb mRNA levels are significantly decreased in the DFosB-positive mice ( Figure 5 ). The results of these two independent approaches in separate groups of animals confirm the results of the cDNA microarray and demonstrate that the expression of the C/EBPb mRNA is significantly decreased in the mice that overexpress DFosB. (a) DFosB immunoreactivity in the hippocampus of the inducible transgenic mice raised in the absence of doxycycline and expressing DFosB (+DFosB) or mice raised in the presence of doxycycline and not expressing DFosB (ÀDFosB). DFosB was analyzed by Western blotting and a representative immunoblot is shown. Two major isoforms of DFosB were observed at 35 and 37 kDa. (b) Immunohistochemistry was conducted on sections from +DFosB and ÀDFosB mice. Representative images are shown for both controls (ÀDFosB) and the overexpressing animals (+DFosB). DFosB is robustly expressed in the CA1 pyramidal cell layer of the hippocampus of +DFosB mice but not of controls. The difference in percentage decreases detected in the separate experiments is likely due to the individual difference among the transgenic mice as well as the difference among the detection approaches. Although there is a trend for levels of C/EBPb immunoreactivity to be decreased in the DFosB-positive mice relative to littermate controls, this effect was not significant ( Figure 5 ).
Downregulation of C/EBPb in the Hippocampus by Chronic ECS Treatment
Downregulation of the C/EBPb expression by DFosB suggests that C/EBPb should be similarly downregulated by chronic ECS treatment. To test this possibility, we analyzed the regulation of C/EBPb in the hippocampus after chronic ECS treatment. The results demonstrate that DFosB, as expected, is increased dramatically in the hippocampus after chronic ECS treatment (Figure 6a ). Moreover, there was a corresponding downregulation of C/EBPb mRNA levels in the hippocampus in response to chronic ECS treatment (Figure 6b ). In contrast, acute ECS treatment did not significantly influence the levels of C/EBPb mRNA (not shown).
DISCUSSION
The present study of the molecular actions of DFosB and ECS treatment combines the powers of two sophisticated strategies, inducible transgenic and microarray technologies. The results demonstrate that induction of DFosB in the hippocampus of inducible transgenic mice, or exposure of normal rats to chronic ECS treatment, downregulates the expression of C/EBPb in this brain region. Given the reported role of C/EBPb in fear conditioning (Carew and Sutton, 2001) , it is possible that the DFosB-mediated downregulation of C/EBPb in the hippocampus may be a molecular mechanism by which antidepressants alleviate some of the symptoms of depressed patients by blocking the formation of new fearful or emotional memories. Previous studies have demonstrated that the expression of DFosB is induced in the hippocampus by repeated antidepressant treatment, particularly ECS, and that the time course for this effect is consistent with the time course for the therapeutic action of antidepressant treatment (Hope et al, 1994) . DFosB is also induced in the nucleus accumbens in response to repeated administration of cocaine and could contribute to the actions of psychostimulants and other drugs of abuse in this brain region The cDNA probes were reverse transcribed from the RNA samples isolated from the hippocampus of the inducible transgenic mice expressing FosB or controls not expressing FosB. Hybridizations were conducted as described in Materials and methods. The ratio of the signal in the mice expressing DFosB relative to that in the absence of DFosB was determined. The results are the average of three separate determinations and are the mean 7 SEM. (Nestler et al, 1999; Nestler, 2001) . The inducible DFosB transgenic mice were developed to study further the molecular and cellular actions of this transcription factor and how they may relate to the actions of antidepressants and other psychotropic drugs. This approach is particularly appropriate because induction of DFosB after removal of doxycycline from the drinking water takes several weeks, similar to the time course for induction of DFosB by antidepressant treatment (Chen et al, 1998) .
In the present study we have used a mouse cDNA microarray containing 4592 different genes to begin to characterize the gene expression profile that results from induction of DFosB in the hippocampus. We have found that several different classes of genes, including protein kinases, receptors, transcription factors, ion channels, protein phosphatases, and proteases are regulated by induction of DFosB. One striking feature is that we consistently observed that regulated genes are decreased, not increased in the DFosB transgenic mice. This supports previous work demonstrating that DFosB can act as a transcriptional repressor because it lacks the C-terminus transactivation domain (Nakabeppu and Nathans, 1991; Nakabeppu et al, 1993) . Additional studies will be required to confirm the regulation of these genes by 
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DFosB using independent methods of analysis. In addition, it will be important to analyze other gene sets to characterize fully the targets that are regulated by DFosB in the hippocampus. C/EBPb was one of the most robustly regulated genes identified in the microarray studies (decreased by more than 70%). In addition, decreased expression of C/EBPb was confirmed by two independent methods, real-time RT-PCR and RNA dot blot in two separate groups of DFosB and littermate control mice. These results firmly establish that the C/EBPb expression is downregulated in the hippocampus by the expression of DFosB. However, levels of C/EBPb immunoreactivity were not significantly decreased in DFosB expressing transgenic mice, although there was a trend for a decrease. This suggests that the downregulation of the C/EBPb mRNA does not result in a corresponding decrease in the levels of the C/EBPb protein. Such an effect could be due to increased efficacy of mRNA translation or decreased degradation of the C/EBPb protein. However, there are several additional possibilities that could lead to a functional outcome. For example, it is possible that the observed small decrease in C/EBPb protein levels, although not significant, could result in decreased function of C/EBPb. It is also possible that C/EBPb protein levels are decreased within certain cell layers or subtypes, for example the dentate gyrus granule cell layer of the CA3 pyramidal cell layers, and that the function of C/EBPb is reduced in these cell layers. Yet another possibility is that C/EBPb is decreased within a particular subcellular compartment (ie nuclear fraction) and that this results in functional alterations. Additional studies will be required to determine the functional consequences of decreased C/EBPb mRNA expression.
In addition to the downregulation of the C/EBPb mRNA in DFosB-expressing transgenic mice, we found that chronic ECS treatment, which increases DFosB expression decreases levels of C/EBPb in the hippocampus. This provides further evidence that DFosB acts as a repressor of the C/EBPb expression. Downregulation of C/EBPb does not appear to be unique to chronic ECS treatment. Other antidepressant treatments such as chronic exposure to fluoxetine are reported to downregulate the expression of C/EBPb significantly (Patel and Lopez, 2001) . While the effects of other chemical antidepressants must be evaluated in future investigations, it is possible that downregulation of C/EBPb may be a common mechanism for antidepressant action.
To understand the molecular mechanisms by which DFosB downregulates C/EBPb, we analyzed the promoter region of the C/EBPb gene for the presence of relevant regulatory elements. The 5 0 flanking sequence of the C/EBPb gene was obtained from the C57/BL6 mouse genome sequence database (UCSC Genome Bioinformatics Site). Analysis of the genomic DNA sequence revealed one AP-1 site (TGACgCA) and one CRE site (TGACGcAg) at the transcription initiation site, which are located 108 nucleotides upstream of the start codon (ATG) of the C/EBPb gene. The AP-1 and CRE sites overlap, which suggests that DFosB could compete with CREB for the binding site and could thereby block the C/EBPb gene transcription. Alternatively, DFosB could compete with other AP-1-binding proteins that stimulate transcription. Future studies will be required to characterize the interaction of transcription factors at the AP-1 and CRE elements in the C/EBPb gene promoter. This will be conducted using promoter-reporter assays in a transfected cell culture system. Another approach to determine if DFosB directly regulates C/EBPb is to use null mutant mice that lack this transcription factor. DFosB is an alternative splice variant of FosB, and based on the hypothesis presented in this study we predict that ECS treatment would not result in downregulation of DFosB in the FosB null mutants.
C/EBPb belongs to a six-member family of transcription factors with structural homologies. The mechanisms by which the regulation of C/EBPb could contribute to the actions of ECS and antidepressant treatment involve regulation of target genes that control learning and memory. The first indication that the C/EBP family of transcription factors may be involved in long-term memory came from studies in Aplysia (Alberini et al, 1994) . In Aplysia, the C/EBP mRNA is induced rapidly by either serotonin or cAMP. Disruption of C/EBP in sensory neurons blocks long-term synaptic facilitation. Further studies in mammalian systems demonstrate that C/EBPb is required for consolidation, but not reconsolidation, of long-term memory in an inhibitory avoidance learning task using electrical foot shocks (Taubenfeld et al, 2001) . Blocking C/EBPb with antisense oligonucleotides disrupts long-term memory of the fearful foot shock and reduces the latency for the animal to enter the dark compartment where it received the foot shock during training. One possible interpretation of the results of the present study is that downregulation of C/EBPb may result in blockade of the formation of aversive and/or emotion-laden memories and thereby contribute to the therapeutic actions of antidepressants.
Analysis of other C/EBP family members has provided evidence that the actions of these transcription factors may be specific to fearful or aversive forms of memory. C/EBPd null mutant mice exhibit enhanced contextual fear conditioning, but there is no effect on spatial memory or short-term contextual memory (Sterneck et al, 1998) . The effect of C/EBPd disruption on memory is different from that of C/EBPb achieved with antisense oligonucleotides, as outlined above. However, these results may not be contradictory because different C/EBP proteins can have different functions (Lekstrom-Himes and Xanthopoulos, 1998). C/EBP dimerization is required for DNA binding, and different C/EBP proteins can heterodimerize with each other as well as with members of other families of transcription factors, leading to a wide range of transcriptional regulation from activation to repression (McKnight, 2001; Ramji and Foka, 2002) . C/EBPd has low affinity for the DNA-binding domain (LekstromHimes and Xanthopoulos, 1998) , and may block the function of C/EBPb by forming heterodimers with lower affinity to specific DNA-binding sites compared to C/EBPb homodimers.
Depression and other mood disorders are complex illnesses that are most likely influenced by several different brain regions, including the amygdala, prefrontal cortex, and the hippocampus Nestler et al, 2002) . The hippocampus is highly sensitive to stress hormones, particularly adrenal-glucocorticoids that are increased by stressful stimuli and are often associated with depressive episodes (Duman et al, 2000; ). In addition, brain imaging studies have demonstrated a reduction of hippocampal volume in depressed patients Nestler et al, 2002) . Adaptations of the hippocampus could directly contribute to the cognitive abnormalities that are observed in depression, and could indirectly influence mood via connections with the amygdala and prefrontal cortex .
How C/EBPb mediates the consolidation of long-term memory for aversive stimuli is still unknown. The inducible DFosB mice could serve as an additional genetic model for exploring the role of C/EBPb in fear conditioning. Further studies in these areas might widen our knowledge of the long-term neural plasticity in response to fearful stimulation as well as provide information for the development of novel antidepressant medications.
